The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital


30 Nov 2021

Victoria makes Australia’s first mRNA vaccine candidate

Victorian scientists and manufacturers have created Australia’s first mRNA COVID-19 vaccine candidate – Australia’s first ever mRNA drug product – in just five months, enabling clinical trials to begin in the new year.

Minister for Innovation, Medical Research and the Digital Economy Jaala Pulford today announced 450 doses of the COVID-19 vaccine candidate have been produced in Boronia, enabling 124 people to take part in Phase 1 clinical trials run by the Doherty Institute and funded by the Australian Government’s Medical Research Future Fund, with results expected later in 2022.

The Andrews Labor Government invested $5 million to enable manufacture of the vaccine candidate, with  dedicated equipment shipped to manufacturer IDT Australia from Canada. The machine processed nanoparticles into final liquid drug form, sterilised the product and filled vials with mRNA vaccine.

Victoria is one of the few places in the world with the capability to develop and manufacture mRNA therapeutics and vaccines and the mRNA-based vaccine breakthrough demonstrates Victoria’s leadership in the mRNA sector.

The project has been led by mRNA Victoria in partnership with Monash Institute of Pharmaceutical Sciences (MIPS), the Doherty Institute and IDT Australia – a landmark collaboration between Victoria’s renowned medical research and manufacturing sectors.

The Labor  Government established mRNA Victoria to drive the establishment of a sovereign mRNA manufacturing industry and earlier this year supported a number of proposals from Victorian industry and consortia as part of the Commonwealth’s Approach to Market (ATM) on mRNA manufacturing capability.

Minister for Innovation, Medical Research and the Digital Economy Jaala Pulford said that this is an Australian first that confirms Victoria as a leader in mRNA therapeutics and manufacturing – it is an incredible achievement to have made an mRNA vaccine candidate that is ready for clinical trials.

“We’re serious about developing our mRNA manufacturing capacity and doing it quickly as we can, because it will save lives,” Minister Pulford said. 

Doherty Institute Head of Vaccine and Immunisation Research Group Professor Terry Nolan said that this is a major milestone in Australia’s ability to manufacture home-grown COVID-19 mRNA vaccines and they are excited to commence Phase 1 clinical trials of this candidate, along with the protein vaccine candidate developed by the Doherty Institute, in the coming months.